文献速递炎症性肠病

炎症性肠病生物制剂治疗及其妊娠期安全性:系统评价与Meta分析

Biologics for Inflammatory Bowel Disease and Their Safety in Pregnancy: A Systematic Review and Meta-analysis.
PubMed 文献 · Clin Gastroenterol Hepatol · 2020-09-12

该系统评价与Meta分析纳入48项研究、6963例患者,评估炎症性肠病妊娠期使用生物制剂的妊娠不良结局。生物制剂暴露下早期妊娠丢失、早产、死产、低出生体重和先天畸形的合并患病率分别为8%、9%、0%、8%和1%,与一般人群相当;孕晚期继续使用TNF抑制剂与早产、低出生体重或先天畸形风险无关。

要点

  • 生物制剂暴露妊娠的早期妊娠丢失合并患病率为8%(95%CI 6%-10%)。
  • 孕晚期继续使用TNF抑制剂与早产、低出生体重、先天畸形风险无关。
  • 生物制剂暴露妊娠的不良结局患病率与一般人群相当。

核心结论

  • 使用生物制剂的炎症性肠病妊娠女性的妊娠不良结局与一般人群相当。

研究设计与样本

  • 系统评价与Meta分析,检索主要数据库自建库至2020年6月,纳入48项研究、6963例患者。

主要发现

  • 早期妊娠丢失合并患病率8%(95%CI 6%-10%;I²=87.4%)。
  • 早产合并患病率9%(95%CI 7%-11%;I²=89.9%)。
  • 死产合并患病率0%(95%CI 0%-0%;I²=0%)。
  • 低出生体重合并患病率8%(95%CI 5%-10%;I²=87.0%)。
  • 先天畸形合并患病率1%(95%CI 1%-2%;I²=78.3%)。

关键数值与推荐

  • 少数研究的亚组分析中,维多珠单抗使用者早期妊娠丢失和早产患病率高于抗TNF使用者。
  • Meta回归未显示疾病活动度或联用硫嘌呤与不良结局相关。
  • 孕晚期继续使用TNF抑制剂与早产风险无关(RR 1.41;95%CI 0.77-2.60;I²=0%)。
  • 孕晚期继续使用TNF抑制剂与低出生体重风险无关(RR 1.32;95%CI 0.80-2.18;I²=0%)。
  • 孕晚期继续使用TNF抑制剂与先天畸形风险无关(RR 1.28;95%CI 0.47-3.49;I²=0%)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Biologics are used routinely in pregnant women with inflammatory bowel disease (IBD), but large-scale data reporting adverse pregnancy outcomes among biologic users are lacking. We sought to estimate the prevalence of adverse pregnancy outcomes in women with IBD on biologic therapies. METHODS: We searched major databases from inception to June 2020 for studies estimating the prevalence of adverse pregnancy outcomes in IBD when using biologics (anti-tumor necrosis factor [TNF], anti-integrins, and anticytokines). Prevalence and relative risk (RR) were pooled using a random-effects model. RESULTS: Forty-eight studies were included in the meta-analysis comprising 6963 patients. Biologic therapy in IBD pregnancies was associated with a pooled prevalence of 8% (95% CI, 6%-10%; I2 = 87.4%) for early pregnancy loss, 9% (95% CI, 7%-11%; I2 = 89.9%) for preterm birth, 0% (95% CI, 0%-0%; I2 = 0%) for stillbirth, 8% (95% CI, 5%-10%; I2 = 87.0%) for low birth weight, and 1% (95% CI, 1%-2%; I2 = 78.3%) for congenital malformations. These rates are comparable with those published in the general population. In subgroup analyses of a small number of studies, the prevalence of early pregnancy loss and preterm birth were higher in vedolizumab vs anti-TNF users. Meta-regression did not show an association of disease activity or concomitant thiopurine on adverse outcomes. Continued TNF inhibitor use during the third trimester was not associated with risk of preterm birth (RR, 1.41; 95% CI, 0.77-2.60; I2 = 0%), low birth weight (RR, 1.32; 95% CI, 0.80-2.18; I2 = 0%), or congenital malformations (RR, 1.28; 95% CI, 0.47-3.49; I2 = 0%). CONCLUSIONS: Adverse pregnancy outcomes among pregnant IBD women using biologics are comparable with that of the general population. PROSPERO protocol #CRD42019135721.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Nielsen OH, Gubatan JM, Juhl CB, et al. Biologics for Inflammatory Bowel Disease and Their Safety in Pregnancy: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2020. PMID: 32931960. doi:10.1016/j.cgh.2020.09.021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。